nejm semaglutide cardiovascular New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Semaglutide cardiovascular outcomes align more

Pregnancy and Breastfeeding Contrave is not recommended during pregnancy or breastfeeding

Aim for a well-rounded diet packed with vegetables, lean proteins, whole grains, and healthy fats

These chargers use the constant current/constant voltage (CC/CV) approach

(She left Community Health Network in November 2025 to spend more time with her family, according to a spokesperson.) All three doctors declined to be interviewed or did not respond to our requests for an interview

7 For patients with type 2 diabetes who have atherosclerotic cardiovascular disease or are at high risk for it or who have kidney disease or heart failure, either a GLP-1 receptor agonist or an SGLT-2 inhibitor with demonstrated cardiovascular benefit with or without metformin is recommended, independent of the hemoglobin A1c level (level of evidence A)